Fidelity Investments
KYMR icon

Fidelity Investments’s Kymera Therapeutics KYMR Stock Holding History

Fidelity Investments’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42B Buy
12,349,256
+649,306
+6% +$55.8M 0.06% 233
2026
Q1 		$974M Buy
11,699,950
+2,771,376
+31% +$219M 0.05% 305
2025
Q4 		$695M Buy
8,928,574
+3,048,963
+52% +$206M 0.04% 396
2025
Q3 		$333M Buy
5,879,611
+447,617
+8% +$20.2M 0.02% 652
2025
Q2 		$237M Buy
5,431,994
+1,022,760
+23% +$35.2M 0.01% 755
2025
Q1 		$121M Sell
4,409,234
-421,189
-9% -$15.4M 0.01% 1015
2024
Q4 		$194M Sell
4,830,423
-278,718
-5% -$12.6M 0.01% 835
2024
Q3 		$242M Buy
5,109,141
+282,301
+6% +$12.5M 0.01% 761
2024
Q2 		$144M Buy
4,826,840
+462,430
+11% +$16M 0.01% 905
2024
Q1 		$175M Buy
4,364,410
+3,829,810
+716% +$137M 0.01% 841
2023
Q4 		$13.6M Sell
534,600
-335,947
-39% -$6.01M ﹤0.01% 1743
2023
Q3 		$12.1M Buy
870,547
+32,335
+4% +$650K ﹤0.01% 1770
2023
Q2 		$19.3M Buy
838,212
+170,861
+26% +$4.9M ﹤0.01% 1654
2023
Q1 		$19.8M Sell
667,351
-178,695
-21% -$5.76M ﹤0.01% 1611
2022
Q4 		$21.1M Buy
846,046
+520,360
+160% +$13.9M ﹤0.01% 1593
2022
Q3 		$7.09M Sell
325,686
-21,098
-6% -$556K ﹤0.01% 2045
2022
Q2 		$6.83M Sell
346,784
-1,577,105
-82% -$36.8M ﹤0.01% 2131
2022
Q1 		$81.4M Sell
1,923,889
-423,638
-18% -$17.9M 0.01% 1163
2021
Q4 		$149M Sell
2,347,527
-8,280
-0.4% -$482K 0.01% 913
2021
Q3 		$138M Buy
2,355,807
+173,378
+8% +$10.1M 0.01% 970
2021
Q2 		$106M Sell
2,182,429
-169,909
-7% -$7.38M 0.01% 1101
2021
Q1 		$91.4M Sell
2,352,338
-89,722
-4% -$5.4M 0.01% 1106
2020
Q4 		$151M Buy
2,442,060
+180,592
+8% +$8.81M 0.01% 863
2020
Q3 		$73.1M Buy
+2,261,468
New +$69M 0.01% 1056

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's KYMR Position: Q2 2026 in Review

Fidelity Investments increased its Kymera Therapeutics (KYMR) stake by 5.5% in Q2 2026, buying an estimated $55.8M and bringing the position to 12,349,256 shares worth $1.42B. The position accounts for 0.06% of the portfolio, ranked #233.

Fidelity Investments first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Fidelity Investments held 12,349,256 shares of Kymera Therapeutics worth $1.42B as of Q2 2026.
  • Fidelity Investments bought 649,306 Kymera Therapeutics shares in Q2 2026, an estimated $55.8M.
  • Kymera Therapeutics made up 0.06% of Fidelity Investments's portfolio in Q2 2026, its #233 holding.
  • Fidelity Investments first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.